Potential new target to combat inflammatory diseases

Potential new target to combat inflammatory diseases

20 November 2020
An international team of researchers have uncovered a drug-like compound that blocks a crucial inflammatory pathway, potentially paving the way for a new treatment for a host of diseases – including COVID-19.

WEHI’s Associate Professor Seth Masters and his research team discovered the compound could prevent upregulation of CD14, a key inflammatory protein. The discovery was recently published in EBioMedicine.

At a glance

  • Researchers have uncovered a drug-like compound that blocks a key inflammatory pathway, involving the immune cell protein CD14.
  • In the laboratory, the compound reduced CD14 levels, limiting inflammation and preventing it from overwhelming the body.
  • The team hope the compound could lead to the development of new medicines for inflammatory diseases, including COVID-19.

Targeting inflammation

A/Prof Seth Masters standing in an office
Associate Professor Seth Masters led the research

Inflammation is our body’s natural reaction to infection, said Associate Professor Masters.

“In the beginning, it helps you fight the infection – but too much inflammation is linked to a range of chronic and acute diseases,” he said.

“In a viral disease such as COVID-19, some patients experience excessive inflammation – called a ‘cytokine storm’ – which can lead to hospitalisation or death. Blocking the CD14 pathway can reduce the severity of many diseases, and potentially save lives.

The team focussed their research on a protein called CD14, that is found on certain inflammatory immune cells called macrophages.

“CD14’s job is to detect infection, helping to drive inflammation to clear a pathogen. But we know that the amount of CD14 increases on macrophages as inflammation progresses, potentially getting out of control, which could lead to worse outcomes for infections or other diseases,” Associate Professor Masters said.

“Our team used CRISPR technology to search for genes that help CD14 levels to rise.

“We found many really interesting genes that were critical – and when we turned these genes off, they could prevent CD14-driven inflammation from overwhelming the body.

“Excitingly, a drug-like inhibitor blocks the protein produced by one of these genes. We found this compound could block the rise in CD14 and consequent inflammation in the laboratory, which is incredibly promising,” Associate Professor Masters said.

Vital first step towards a treatment

Microscope image showing inflammation
Tissue stained to highlight sites of inflammation caused by
taking away an anti-inflammatory protein found in the skin. 
Image: Nima Etemadi

Associate Professor Masters said the discovery of a potential anti-inflammatory compound opened the doors for new anti-inflammatory therapies.

“If this compound could be developed into a safe and effective drug, it could potentially assist in the treatment of many inflammatory diseases. However, once available, the drug would only be beneficial for curbing severe inflammation.

“Inflammation is a critical process for fighting many infectious, so we only need to use an anti-inflammatory drug for the most severe and life-threatening forms of inflammation,” Associate Professor Masters said.

“The next step in this research would be to see if this drug candidate worked against particular diseases in pre-clinical trials. There is great hope this research will one day be translated into an effective treatment for inflammatory illnesses.”

The research was supported by a Viertel Senior Medical Research Foundation Fellowship (SLM), the European Union’s Horizon 2020 research and innovation program, and the Australian and Victorian governments. GSK funded aspects of the research.


Media inquiries

M: +61 475 751 811 
E: communityrelations@wehi.edu.au


Super Content: 
Researcher facing news media crews

Catch up on our latest research discoveries and announcements.

Research team in a lab

Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate

Visualisation of SARS-CoV-2

Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak as well as in preparedness for likely future coronaviral disease outbreaks.

Two researchers in a laboratory

Researchers have uncovered clues in the immune system that reveal how the balance of ‘good’ gut bacteria is maintained.

The information could help in the prevention and treatment of inflammatory bowel disease (IBD).

DNA graphic

Dr Marco Herold speaks to ABC TV’s Catalyst program about new ways to fight cancer with CRISPR and Cas9

Developing intestinal buds, colours highlight the proteins involved in growth

Dr Tracy Putoczki presents her research findings into targeting cytokines in inflammatory diseases with a focus on Interkeukin-11.